JAN 1 0 2002 PA

PTO/SB/63 (10-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE in Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docke Docke

Docket Number (Optional) 4673120/4650

In re Application of: Kreamer Name: Jeffry Kreamer Application Number: 08/071,052 Filed: June 4, 1993 For: Aspirin and Vitamin and/or Trace Element Compositions for the Amelioration and Treatment of Vascular Disease The owner, Kreamer of 100 percent interest in the above-identified application hereby disclaims a terminal part of the term of any patent granted the above-identified application hereby disclaims a terminal part of the term of any patent granted the above-identified application, and (2) if the above-identified application, is a design application, the period of abandonment of the application; or (b) the period extending beyond twenty years from the date on which the period of abandonment of the application; or (b) the period extending beyond twenty years from the date on which the period of abandonment of the application; or (b) the period extending beyond twenty years from the date on which the period of abandonment of the application; or (b) the period extending beyond twenty years from the date on which the period of abandonment of the application; or (b) the period extending beyond twenty years from the date on which the period of abandonment of the application; or (b) the period extending beyond twenty years from the date on which the period of abandonment was filed. This disclaimer also applies to any patent granted on a utility or plant application filed before June 8, 1995, or a design application, that contains a specific reference under 35 U.S.C. 120, 121, or 365(c) to the above-identified application. This disclaimer is binding upon the grantee, and its successors or assigns. Check either box 1 or 2 below, if appropriate. 1. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization. 2. The undersigned is an attorney or agent of record. WARNING: Information on this form may become public. Credit card information on PTO-2038. * Statement under 37 CFR 3.73(b) i	TERMINAL DISCLAIMER TO ACCOMPANY PETITION	4673120/4650	
nereby disclaims a terminal part of the term of any patent granted the above-identified application equivalent to: (1) if the above-identified application is a design application, the period of abandonment of the above-identified application, and (2) if the above-identified application, and (2) if the above-identified application, and (2) if the apove-identified application is a utility or plant application, the lesser of: (a) the period of abandonment of the application; or (b) the period extending beyond twenty years from the date on which the above-identified application was filed in the United States or, if the application contains a specific reference to an earlier filed application(s) under 35 U.S.C. 120, 121, or 365(c), from the date on which the earliest such application was filed. This disclaimer also applies to any patent granted on a utility or plant application filed before June 8, 1995, or a design application, that contains a specific reference under 35 U.S.C. 120, 121, or 365(c) to the above-identified application. This disclaimer is binding upon the grantee, and its successors or assigns. Check either box 1 or 2 below, if appropriate. 1. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization. 2. The undersigned is an attorney or agent of record. Kent. A. Herink Typed or printed name Terminal disclaimer fee under 37 CFR 1.20(d) included. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.	Name: Jeffry Kreamer Application Number: 08/071,052 Filed: June 4, 1993 For: Aspirin and Vitamin and/or Trace Element Compositions for the		
1. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization. 2. The undersigned is an attorney or agent of record.	hereby disclaims a terminal part of the term of any patent granted the above-identified application equivalent to: (1) if the above-identified application is a design application, the period of abandonment of the above-identified application, and (2) if the above-identified application is a utility or plant application, the lesser of: (a) the period of abandonment of the application; or (b) the period extending beyond twenty years from the date on which the above-identified application was filed in the United States or, if the application contains a specific reference to an earlier filed application(s) under 35 U.S.C. 120, 121, or 365(c), from the date on which the earliest such application was filed. This disclaimer also applies to any patent granted on a utility or plant application filed before June 8, 1995, or a design application, that contains a specific reference under 35 U.S.C. 120, 121, or 365(c) to the above-identified application. This disclaimer is binding upon the grantee, and		
agency, etc.), the undersigned is empowered to act on behalf of the organization. The undersigned is an attorney or agent of record. Signature Date Kent. A. Herink Typed or printed name Terminal disclaimer fee under 37 CFR 1.20(d) included. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. * Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).	Check either box 1 or 2 below, if appropriate.		
Signature // o/2002			
Kent. A. Herink Typed or printed name Terminal disclaimer fee under 37 CFR 1.20(d) included. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. * Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).	2. K The undersigned is an attorney or agent of record.		
Typed or printed name Typed or printed name Typed or printed name Typed or printed name WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. * Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).	Menta He Signature	// 0/2002 Date	
Terminal disclaimer fee under 37 CFR 1.20(d) included. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. * Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).			
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. * Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).			
included on this form. Provide credit card information and authorization on PTO-2038. * Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).	Terminal disclaimer fee under 37 CFR 1.20(d) included.		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case and complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

JAN 1 7 2002